Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Somers

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
Cancer|November 1, 1983
Sequential non-cross-resistant chemotherapy regimens (MOPP and CAVmP) in Hodgkin's disease stage IIIB and IVD J Wagener, J M Burgers, A W Dekker, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1987
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma GroupH T Mouridsen, L Bastholt, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative GroupI Teodorovic, S Pittaluga, J C Kluin-Nelemans, et al.
JBMR Plus|March 13, 2020
Severe Primary Hyperparathyroidism Caused by Parathyroid Carcinoma in a 13-Year-Old Child; Novel Findings From HRpQCTNina Lenherr-Taube, Carol Kl Lam, Reza Vali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1994
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damageF E van Leeuwen, A M Chorus, A W van den Belt-Dusebout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Second cancer risk following Hodgkin's disease: a 20-year follow-up studyF E van Leeuwen, W J Klokman, A Hagenbeek, et al.
Heart Rhythm|October 8, 2017
Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular functionTomas Konecny, Kiran R Somers, Jae Yoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study GroupU Tirelli, D Errante, M Van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative GroupA Hagenbeek, P Carde, J H Meerwaldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma GroupP Carde, J H Meerwaldt, M van Glabbeke, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
Cancer|November 1, 1983
Sequential non-cross-resistant chemotherapy regimens (MOPP and CAVmP) in Hodgkin's disease stage IIIB and IVD J Wagener, J M Burgers, A W Dekker, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1987
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma GroupH T Mouridsen, L Bastholt, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative GroupI Teodorovic, S Pittaluga, J C Kluin-Nelemans, et al.
JBMR Plus|March 13, 2020
Severe Primary Hyperparathyroidism Caused by Parathyroid Carcinoma in a 13-Year-Old Child; Novel Findings From HRpQCTNina Lenherr-Taube, Carol Kl Lam, Reza Vali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1994
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damageF E van Leeuwen, A M Chorus, A W van den Belt-Dusebout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Second cancer risk following Hodgkin's disease: a 20-year follow-up studyF E van Leeuwen, W J Klokman, A Hagenbeek, et al.
Heart Rhythm|October 8, 2017
Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular functionTomas Konecny, Kiran R Somers, Jae Yoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study GroupU Tirelli, D Errante, M Van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative GroupA Hagenbeek, P Carde, J H Meerwaldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma GroupP Carde, J H Meerwaldt, M van Glabbeke, et al.
Pageof 21